KVANTO-PAYMENT-SOLUTIONS
6.2.2020 09:02:10 CET | Business Wire | Press release
For Pure Health inc. (FPH) has signed a partnership agreement with Kvanto Payment Services A/S (hereafter Kvanto). FPH provides sales all over the globe. All numbers and assumptions are based on previous first-hand experience with similar setups and products. And has made it before and they have entered with Kvanto and using the Payment Gateway, this has a large opportunity.
“FPH was looking for a partner to handle payments solution. One of the most important things for FPH is that customers experience has a smooth and secure checkout when buying our products from our website.
Kvanto Payment services not only provided us with this solution but also helped us set up the system, quickly and seamlessly. Furthermore, FPH has trusted Kvanto Payment Services with helping FPH with administration, technical, and development.
This special cooperation we have not been able to find elsewhere. From the start of this cooperation, we have made this as a focus development case, and we are now moving it to a slot of large opportunities of 250M € turnover a year and our aim is larger, and Kvanto stands the challenge and we have been satisfying so fare.
Allan Djurhuus
CEO, FPH Inc
.”
Benefits compared to other solution partners
Kvanto has an MPI security Solution, it works outside Europe, and that’s where we have most of the clients in FPH. Kvanto makes sure the merchant’s customer and the cardholder are the same person by sending a code to the customer's cell phone, which the customer must fill into the payment window before the payment is approved.
FPH has made this happen, through our marketing corporation with Konnektive CRM in US/PR and we have worked with Konnektive CRM for years now, and it has been a huge success, and we are so delighted to manage to get both Kvanto and Konnektive CRM together, and we have now one solution, and that saves us a large amount of time and money, we can´s understand why people not are managing this as it has to be, and as Konnektive is saying.
“Time is money.
With hundreds of integrations through Konnektive, you’ll never be scrambling to find your data by going to multiple systems. We put everything you need at your fingertips; all in one place!
Konnektive CRM was designed to Automate
and Synchronize
Your Entire Business with the easiest, most intuitive user interface.
Brian Bolerjack,
Konnektive CRM”
Kvanto cooperation with both the system provider and customer
Kvanto has made an option and an opportunity by creating this cooperation, to manage a whole platform, by offering the Kvanto ESB Payment Gateway, and support the individual customer and the whole group of Konnektive CRM platform solution, as a trusted partner. Kvanto has proved to be highlighted as a service provider that can handle payment transactions across the payment ECO-system, and even if you are making the payment happen in Europe or elsewhere, we can carry the solution to a new level of security by Kvanto MPI solution.
Value proposition
By managing this, and through the Kvanto Gateway Solution, it will be possible to draw more potential clients into our merchants, and our expectation of this cooperation is more than 12 Mill $ in turnover a year, on this case alone.
And the options for new clients is much higher, and we can multiply this 3-4 times.
This is an optimizing way of creating new clients, and we have today two new clients, that bring more merchants in through this cooperation, and we expect to reach some 15-22 clients with the support we have from Konnektive CRM staff and PR from FPH.
About Kvanto Payment Solutions
Kvanto is a Payment Solution Provider company that provides simple, flexible, and cost-efficient payment solutions on the global market. Through experience and knowledge does Kvanto challenge current structures and procedures in the established market.
Kvanto strives to be a one-stop-shop for payments with cross border solutions for merchants and the leading EMEA/APAC multi-connectivity payment solutions provider measured in processing volume while being profitable.
For further investor enquires
Listing Partners LLC
support@listingpartners.lu
All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. Kvanto Payment Systems A/S is under no obligation to (and expressly disclaim any such obligation to) update or alters our forward-looking statements, whether as a result of new information, future events, or otherwise.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200206005045/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
